First Trust创新领袖主动型ETF ILDR 深 沪
等待开盘 04-03 09:30:00 美东时间
30.26
-0.050
-0.16%
华盛通- 最 高30.47
- 今 开29.69
- 成交量 4.18万股
- 最 低 29.635
- 昨 收 30.31
- 总市值 2.12亿
- 52周最高 35.28
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 21.3711
- 委 比 0.00%
- 总股本 700.00万
- 历史最高 35.28
- 量 比 1.12
- 振 幅 2.75%
- 历史最低 13.109
- 每 手 1
- 风险率 3.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
BRIEF-Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS : SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUP
03-16 19:34
BRIEF-The Children’S Place Announces Senior Leadership Appointments
BRIEF-The Children’S Place Announces Senior Leadership Appointments Children's Place Inc PLCE.O : THE CHILDREN’S PLACE ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS Source text: ID:nGNXkMb2t Further company coverage: PLCE.O
02-24 22:18
BRIEF-Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children
BRIEF-Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children Feb 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T : POSITIVE PHASE 3 DATA DEMONSTRATE POTENTIAL FOR ENTYVIO® (VEDOLIZUMAB) TO ADDRESS TREATMENT GAP FOR CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE ULCERATIVE CO
02-20 01:40
BRIEF-Air Canada Foundation Launches Big Dreams Grant Program
BRIEF-Air Canada Foundation Launches Big Dreams Grant Program Feb 9 (Reuters) - Air Canada AC.TO : AIR CANADA FOUNDATION LAUNCHES BIG DREAMS GRANT PROGRAM SUPPORTING THE HEALTH AND WELL-BEING OF CHILDREN AND YOUTH THROUGH ACTIVE RECREATION AND SPORTS, INSPIRED BY THE SPIRIT OF TEAM CANADA Source tex
02-09 22:46
BRIEF-Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia)
BRIEF-Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia) Feb 3 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O : ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM DATA DEMONSTRATING TREATMENT WITH UX111 GENE THERAPY RESULTS
02-03 21:09
BRIEF-US Weighs Tapping Robinhood For ‘Trump Accounts’ For Children - Bloomberg News
BRIEF-US Weighs Tapping Robinhood For ‘Trump Accounts’ For Children - Bloomberg News Jan 29 (Reuters) - US WEIGHS TAPPING ROBINHOOD FOR ‘TRUMP ACCOUNTS’ FOR CHILDREN - BLOOMBERG NEWS Source text: https://tinyurl.com/22yqmrwl Further company coverage: HOOD.O (( Reuters.Briefs@thomsonreuters.com ;))
01-30 05:12
FACTBOX-India's vast internet, social media apps market
FACTBOX-India's vast internet, social media apps market BENGALURU, Jan 29 (Reuters) - India is one of the most critical growth markets for social media companies, which are now facing calls to limit access to young people, amid fears of "digital addiction". Here are facts about India's vast internet
01-29 17:58
BRIEF-European Commission approves Guerbet's half-dose GBCA, Elucirem for newborns and children
BRIEF-European Commission approves Guerbet's half-dose GBCA, Elucirem for newborns and children Jan 27 (Reuters) - Guerbet SA GRBT.PA : NEW INDICATION IN CHILDREN FROM BIRTH FOR GUERBET'S HALF-DOSE GBCA, ELUCIREM™ (GADOPICLENOL) APPROVED BY EUROPEAN COMMISSION Source text: ID:nPremYxm5a Further comp
01-28 01:06
42West Scores Six Oscar Nominations for Dolphin Entertainment
42West Scores Six Oscar Nominations for Dolphin Entertainment 42West, a subsidiary of Dolphin Entertainment Inc. (NASDAQ:DLPN), secured six client nominations at the 98th Academy Awards. The nominations include Netflix’s TRAIN DREAMS for Best Picture, THE ALABAMA SOLUTION for Best Documentary Featur
01-26 22:00
BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma
Dec 23 (Reuters) - Sanofi SA SASY.PA: SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMON...
2025-12-23 14:02
